wire - news in brief

« BACK

Health



Results 1601 - 1650 of 1695.
« Previous 1 ... 29 30 31 32 33 ... 34 Next »


Business / Economics - Health - 26.08.2010
Novartis completes 77% majority ownership of Alcon
Novartis completes 77% majority ownership of Alcon adding new growth platform in eye care to its leading healthcare portfolio Alcon strategically complements Novartis' portfolio, adding a world class

Health - Life Sciences - 24.08.2010
Swiss delegation led by Federal Councillor Didier Burkhalter travels to Brazil to discuss health and scientific cooperation
Bern, 24.08.2010 - From 25-30 August, a high-ranking scientific delegation led by Federal Council Didier Burkhalter will be travelling to Brazil for the purpose of consolidating relations between the two countries.

Health - Life Sciences - 23.08.2010

Chemistry - Health - 02.08.2010
IBM and University of Aberdeen collaborate to identify molecules from the deep sea
For the first time, atomic force microscopy helps scientists reveal the exact chemical structure of a natural compound Aberdeen, Scotland and Zurich, Switzerland, August 2, 2010—In a pioneering research project, for the first time, scientists at IBM (NYSE: IBM) and the University of Aberdeen have collaborated to “see” the structure of a marine compound from the deepest place on the Earth using an atomic force microscope (AFM).

Health - Business / Economics - 23.07.2010
Sandoz leads the way with first generic version of ’gold standard’ anti-thrombotic Lovenox [1]
Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox Sandoz is the first company to receive US approval to market a more affordable generic version of the leadin

Health - Physics / Nanosciences / Material science - 22.07.2010
New X-ray technique distinguishes between that which previously looked the same
New X-ray technique distinguishes between that which previously looked the same
A new method forms the basis for the widespread use of an X-ray technique which distinguishing types of tissue that normally appear the same in conventional X-ray images. Traditional X-ray images can clearly distinguish between bones and soft tissue, with muscles, cartilage, tendons and soft-tissue tumours all look virtually identical.

Health - 20.07.2010
Novartis receives approval in China for Rasilez, a first-in-class direct renin inhibitor for high blood pressure, the leading preventable cause of death in China
Novartis receives approval in China for Rasilez, a first-in-class direct renin inhibitor for high blood pressure, the leading preventable cause of death in China Rasilez provides significant blood pr

Health - Business / Economics - 14.07.2010
Plaintiffs and Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, agree to resolve all gender discrimination claims associated with class action
Plaintiffs and Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, agree to resolve all gender discrimination claims associated with class action · Agreement reached between Novarti

Health - Life Sciences - 01.07.2010
Phase III study shows Novartis drug Afinitor more than doubles time without tumor growth in advanced pancreatic NET patients
Phase III study shows Novartis drug Afinitor more than doubles time without tumor growth in advanced pancreatic NET patients Everolimus extended median progression-free survival from 4.6 to 11.0 months vs.

Life Sciences - Health - 25.06.2010
Microbial protein restores vision in blind animals
June 25, 2010 Microbial protein restores vision in blind animals Scientists from the Friedrich Miescher Institute for Biomedical Research (FMI) restore vision in retinitis pigmentosa using an archaebacterial protein. Introducing halorhodopsin into the remaining but nonfunctional cone photoreceptors of the retina of mice not only reactivates the cone cells' ability to interact with the rest of the visual system, it also prompts sophisticating visually guided behavior.

Health - Life Sciences - 18.06.2010
FDA approves Tasigna for newly diagnosed chronic myeloid leukemia patients, data demonstrate major advance over Glivec
FDA approves Tasigna for newly diagnosed chronic myeloid leukemia patients, data demonstrate major advance over Glivec In head-to-head trial, Tasigna reduced leukemia-causing protein faster than Glivec, resulting in lower rates of cancer progression even as early as 12 months Regulatory submissions under way worldwide, with applications currently filed in the EU, Switzerland and Japan Basel, June 17, 2010 - Following a priority review, the US Fo

Health - 18.06.2010
New Phase II study in gout patients shows Novartis ACZ885 prevented acute flares better than standard anti-inflammatory therapy
New Phase II study in gout patients shows Novartis ACZ885 prevented acute flares better than standard anti-inflammatory therapy ACZ885 significantly reduced rate of acute flares up to 75% vs.

Health - Business / Economics - 11.06.2010
FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS
FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS Committee voted in favor of approval of FTY720 (fingolimod), as treatment in relapsing remitting multiple sclerosis, affirming the drug's positive benefit/risk profile FTY720, potentially first in a new class of MS therapy, represents a significant advance as an efficacious oral treatment for people with relapsing r

Health - Life Sciences - 05.06.2010
Study at ASCO shows Novartis drug Afinitor first to shrink SEGA brain tumors in children and adults with tuberous sclerosis
Study at ASCO shows Novartis drug Afinitor first to shrink SEGA brain tumors in children and adults with tuberous sclerosis Phase II study shows meaningful reduction in brain tumor size in 75% of patients with subependymal giant cell astrocytomas (SEGAs) from baseline to six months SEGAs are benign brain tumors associated with tuberous sclerosis (TS) that primarily affect children and adolescents and can cause severe brain swelling No patient de

Health - 05.06.2010
Adding Novartis drug Zometa to chemotherapy significantly improved overall survival in study of newly diagnosed multiple myeloma patients
View all media releases June 05, 2010 14:15 CET Adding Novartis drug Zometa to chemotherapy significantly improved overall survival in study of newly diagnosed multiple myeloma patients This press release is not intended for United Kingdom news media Phase III data show Zometa, a bone-targeted agent, provided significant clinical anticancer benefit and significantly reduced risk of skeletal-related events Survival advantage observed with Zometa

Health - Chemistry - 04.06.2010
New data at ASCO show Novartis drug Tasigna surpasses Glivec in slowing disease progression for newly diagnosed CML patients
View all media releases June 04, 2010 07:15 CET New data at ASCO show Novartis drug Tasigna surpasses Glivec in slowing disease progression for newly diagnosed CML patients 18-month median follow-up from the first head-to-head comparison of these two oral therapies to be presented Monday, June 7 at ASCO In this study, Tasigna produced deeper molecular responses and significantly reduced progression to advanced disease, resulting in fewer deaths

Physics - Health - 03.06.2010
Physicists and medics set out strategy on physics for health
Geneva 3 June 2010. Following a workshop hosted by the CERN 1 European particle physics laboratory in February, doctors and physicists today published a strategy for harnessing physics for health.

Health - Business / Economics - 03.06.2010
Pivotal Phase III trial of Novartis drug Afinitor met primary endpoint in study of patients with advanced pancreatic neuroendocrine tumors
Pivotal Phase III trial of Novartis drug Afinitor met primary endpoint in study of patients with advanced pancreatic neuroendocrine tumors RADIANT-3 study results show everolimus significantly extend

Health - Life Sciences - 02.06.2010
Data at ASCO show promise of Novartis drugs for patients with life-threatening diseases like CML, multiple myeloma and breast cancer
Data at ASCO show promise of Novartis drugs for patients with life-threatening diseases like CML, multiple myeloma and breast cancer Pipeline data, including panobinostat (LBH589), PI3K Inhibitors BE

Health - Business / Economics - 27.05.2010
Novartis Phase III trial examining EPO906 (patupilone) for patients with advanced ovarian cancer failed to meet primary endpoint
Novartis Phase III trial examining EPO906 (patupilone) for patients with advanced ovarian cancer failed to meet primary endpoint Basel, May 27, 2010 - Novartis announced today that patupilone (EPO906) did not show a significant overall survival advantage in a phase III trial of patients with advanced ovarian cancer, refractory or resistant to platinum-based therapy The comparator arm in the trial was Doxil /Caelyx (pegylated liposomal doxorubicin).

Health - Administration - 25.05.2010
Novartis announces extension of US regulatory priority review period for FTY720, an investigational once-daily oral multiple sclerosis therapy
Novartis announces extension of US regulatory priority review period for FTY720, an investigational once-daily oral multiple sclerosis therapy US Food and Drug Administration (FDA) extends priority r

Health - Life Sciences - 22.05.2010
Ranibizumab significantly more effective than standard of care in treating vision loss due to DME, a serious complication of diabetes
Ranibizumab significantly more effective than standard of care in treating vision loss due to DME, a serious complication of diabetes Study shows around 40% of ranibizumab patients substantially impr

Health - Life Sciences - 11.05.2010
Swiss scientists sequence fire blight genome
Swiss scientists sequence fire blight genome
Wädenswil, 11.05.2010 - Researchers at Agroscope Changins-Wädenswil ACW have published the first complete genome sequence of the fire blight pathogen, Erwinia amylovora.

Business / Economics - Health - 05.05.2010

Health - Life Sciences - 04.05.2010
Mechanism elucidated for a rare disease
Scientists at the Friedrich Miescher Institute for Biomedical Research (FMI, part of the Novartis Research Foundation) have dissected one of the molecular mechanisms underlying Friedreich's ataxia. In doing so, they have shed new light on the pathogenic mechanism of the disease. These findings could lead to the development of new therapeutic approaches for what is, as yet, an incurable condition.

Life Sciences - Health - 26.04.2010
Odors classified by networks of neurons
Odors classified by networks of neurons
Scientists at the Friedrich Miescher Institute for Biomedical Research (FMI, part of the Novartis Research Foundation), are unraveling how odors are processed by the brain. As they report, odors in the olfactory brain are classified into groups represented by discrete activity states of neuronal circuits.

Health - Life Sciences - 23.04.2010
Novartis gains new indication for Diovan for the treatment of children and adolescents with high blood pressure in the EU
Novartis gains new indication for Diovan for the treatment of children and adolescents with high blood pressure in the EU New indication brings the world's number one selling high blood pressure medi

Health - Life Sciences - 22.04.2010
Novartis receives US FDA approval for Zortress® (everolimus) to prevent organ rejection in adult kidney transplant recipients
Novartis receives US FDA approval for Zortress® (everolimus) to prevent organ rejection in adult kidney transplant recipients Zortress offers kidney transplant recipients a new option for preventing

Health - Business / Economics - 22.04.2010
Novartis receives US FDA approval for Zortress (everolimus) to prevent organ rejection in adult kidney transplant recipients
Novartis receives US FDA approval for Zortress (everolimus) to prevent organ rejection in adult kidney transplant recipients Zortress offers kidney transplant recipients a new option for preventing o

Business / Economics - Health - 20.04.2010
Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation, growth and productivity
Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation , growth and productivity Net sales up 25% (+18% in constant currencies, or cc) to US

Health - Business / Economics - 19.04.2010
Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products targeting asthma and COPD
Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products targeting asthma and COPD ·         Sandoz gains rights to three promising development projects, as well as t

Health - Business / Economics - 13.04.2010
Novartis investigational multiple sclerosis therapy Gilenia®* (FTY720) shown to reduce relapse rates regardless of treatment history
Basel, April 13, 2010 - Data presented at the American Academy of Neurology (AAN) annual meeting add to the accumulating evidence of the positive benefit/risk profile of Gilenia, a potential first-in-class, once-daily oral therapy for relapsing forms of multiple sclerosis (MS).

Health - Business / Economics - 13.04.2010
Novartis investigational multiple sclerosis therapy Gilenia * (FTY720) shown to reduce relapse rates regardless of treatment history
Novartis investigational multiple sclerosis therapy Gilenia * (FTY720) shown to reduce relapse rates regardless of treatment history New extension data show Gilenia effect sustained over two years; also highlights potential benefits of switching from interferon beta-1a Basel, April 13, 2010 - Data presented at the American Academy of Neurology (AAN) annual meeting add to the accumulating evidence of the positive benefit/risk profile of Gilenia, a potential first-in-class, once-daily oral therapy for relapsing forms of multiple sclerosis (MS).

Health - Life Sciences - 09.04.2010
Strengthening stem cell research in Switzerland
When it comes to treating incurable diseases, hopes are high for stem cells because they can develop into a multitude of specialized cells. But despite rapidly accumulating and promising results - stem cells are for instance implicated in the treatment of Type 1 diabetes- the nature, function and differentiation capacity of stem cells are still poorly understood.

Health - Life Sciences - 18.03.2010
Novartis receives approval in the European Union for Menveo®, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease
Basel, March 18, 2010 - Novartis announced today that the European Commission (EC) granted a Marketing Authorization for Menveo ® (Meningococcal Group A, C, W135 and Y conjugate vaccine) in all 27 European member states. Menveo is indicated for the active immunization of adolescents (from 11 years of age) and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.

Health - Life Sciences - 18.03.2010
Novartis receives approval in the European Union for Menveo , first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease
Novartis receives approval in the European Union for Menveo , first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease Meningococcal disease is a major cause of bacterial

Health - Business / Economics - 16.03.2010
Exploratory trial shows no incremental benefit of aliskiren add-on therapy in improving changes to cardiac shape in heart attack patients
Exploratory trial shows no incremental benefit of aliskiren add-on therapy in improving changes to cardiac shape in heart attack patients ·       Trial assessed addition of aliskiren to help limit changes to the heart's shape and function in patients after heart attack (post-myocardial infarction) ·       A small numerical reduction in cardiac volume from adding aliskiren to standard therapy seen in echocardiogram results, but not statistically

Health - Life Sciences - 16.03.2010
The Friedrich Miescher Institute for Biomedical Research turns 40!
The Friedrich Miescher Institute for Biomedical Research turns 40!
March 16 2010 The Friedrich Miescher Institute for Biomedical Research turns 40! Today, the Friedrich Miescher Institute for Biomedical Research, part of the Novartis Research Foundation, is celebrating its 40th birthday.

Health - Life Sciences - 16.03.2010
The Friedrich Miescher Institute for Biomedical Research turns 40!
Today, the Friedrich Miescher Institute for Biomedical Research, part of the Novartis Research Foundation, is celebrating its 40th birthday.

Health - Life Sciences - 16.03.2010
EPFL becomes world center for tuberculosis study
Tuberculosis still affects thousands of victims worldwide.

Health - Life Sciences - 14.03.2010
NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk cardiovascular patients with impaired glucose tolerance
NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk cardiovascular patients with impaired glucose tolerance NAVIGATOR study involved more than 9,000 patients, making it one of the largest and longest global trials to date in pre-diabetic patients Basel, March 14, 2010 - Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.

Health - Business / Economics - 10.03.2010
Novartis announces USD 5 billion bond issue
These notes are registered with the U.S. Securities and Exchange Commission under an automatic shelf registration statement filed by Novartis in 2008.

Event - Health - 09.03.2010
FBM Talents of the year 2010
Premier rang de gauche à droite: Oscar Matzinger, Marie-Denise Schaller, Marie-Claude Hofner, Patrice Guex, Nicolas Salamin.

Business / Economics - Health - 26.02.2010
Shareholders approve all proposed resolutions of Novartis Board of Directors
Shareholders approve 14 th consecutive dividend increase to CHF 2.20 (+5%) per share for 2010, representing a payout of approximately 55% of net income from continuing operations, marking cont

Health - Administration - 22.02.2010
Novartis receives FDA approval of Menveo®, a vaccine to prevent meningococcal disease
Basel, February 22, 2010 - Novartis announced that Menveo® (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine), a quadrivalent meningococcal conjugate vaccine was approved by the US Food and Drug Administration (FDA) for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people 11 to 55 years of age[1].

Health - Business / Economics - 22.02.2010
Novartis oral multiple sclerosis development compound Gilenia®* (FTY720) granted US priority review status
Basel, February 22, 2010 - Gilenia®* (FTY720, fingolimod) has been granted priority review status by the US Food and Drug Administration (FDA), which accepted the regulatory submission made in December 2009 for this medicine. Once-daily Gilenia  (0.5 mg) has the potential to become the first approved oral therapy for the treatment of multiple sclerosis (MS).

Health - Life Sciences - 19.02.2010
Novartis drug Tasigna® receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia
Basel, February 19, 2010 - Novartis announced today that Tasigna® (nilotinib) has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. FDA priority review status is granted to therapies that offer major advances in treatment or provide a treatment where no adequate therapy exists.

Health - Life Sciences - 09.02.2010
Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C therapy
Phase II results demonstrate efficacy of Debio 025, a cyclophilin inhibitor, against hepatitis C virus when used alone or in combination with current standard therapy 1 Basel, February 9, 2010 - Novartis has gained exclusive rights to develop and market Debio 025 (alisporivir), a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C. Debio 025 is the first in a new class of drugs called cyclophilin inhibitors which could become part of the future standard of care for the disease.

Health - Media - 27.01.2010
Ein fataler Kreislauf
Zurich - University of Zurich Eine Studie der Psychiatrischen Universitätsklinik Zürich hat erstmals die Schweizer Drogenpolitik von 1975 bis 2007 untersucht.
« Previous 1 ... 29 30 31 32 33 ... 34 Next »